Risk factor
Poor trading liquidity
Profitability factor
Favourable price performance
About
Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifungals, anesthetics, immunosuppressants, and intermediates for antifungal treatments. It also produces lyophilized injectable pharmaceuticals, covering diverse therapeutic areas such as antibiotics, antifungals, cardiac care, infertility solutions, antivirals, and proton-pump inhibitors. Additionally, Gufic Biosciences provides pharmaceutical products under its Spark, Criti Care, and Ferti Care brands, as well as a line of herbal and personal care items. The company distributes its extensive product portfolio to hospital networks and medical facilities, and it exports its goods to over twenty countries globally. Established in 1970, Gufic Biosciences Limited is headquartered in Mumbai, India.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA